Agios Pharmaceuticals
NYSE
Agios Pharmaceuticals's latest marketcap:
As of 06/08/2025, Agios Pharmaceuticals's market capitalization has reached $1.99 B. According to our data, Agios Pharmaceuticals is the 6060th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.99 B |
| Revenue (ttm) | 37.04 M |
| Net Income (ttm) | 665.98 M |
| Shares Out | 57.92 M |
| EPS (ttm) | 11.45 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/31/2025 |
Agios Pharmaceuticals's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | $1.99 B | 6.09% |
| 12/31/2024 | $1.87 B | 50.56% |
| 12/29/2023 | $1.24 B | -19.33% |
| 12/30/2022 | $1.54 B | -13.57% |
| 12/31/2021 | $1.79 B | -40.52% |
| 12/31/2020 | $3 B | 6.73% |
| 12/31/2019 | $2.81 B | 4.81% |
| 12/31/2018 | $2.68 B | -3.76% |
| 12/29/2017 | $2.79 B | 58.97% |
| 12/30/2016 | $1.75 B | -28.25% |
Company Profile
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines in the field of cellular metabolism. Headquartered in Cambridge, Massachusetts, the company was founded in 2007 and is dedicated to addressing unmet medical needs through cutting-edge research.
Key Products & Pipeline
- PYRUKYND (mitapivat) – A pyruvate kinase (PK) activator for treating hemolytic anemias in adults with PK deficiency. It is also under investigation for:
- Sickle cell disease (Phase 3 clinical trial)
- Pediatric PK deficiency
- Alpha- or beta-thalassemia in adults
- Tebapivat – A PK activator targeting lower-risk myelodysplastic syndrome and hemolytic anemias.
- AG-181 – A phenylalanine hydroxylase stabilizer for phenylketonuria (PKU) treatment.
- AG-236 – An siRNA therapy targeting TMPRSS6 for polycythemia vera, developed in collaboration with Alnylam.
Agios Pharmaceuticals continues to advance its pipeline, leveraging its expertise in cellular metabolism to develop transformative therapies for patients worldwide.
Frequently Asked Questions
-
What is Agios Pharmaceuticals's (AGIO) current market cap?As of 06/08/2025, Agios Pharmaceuticals (including the parent company, if applicable) has an estimated market capitalization of $1.99 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Agios Pharmaceuticals (AGIO) rank globally by market cap?Agios Pharmaceuticals global market capitalization ranking is approximately 6060 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.